Nothing but good clean fun
Nothing but good clean fun
Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Amdocs Limited ("Amdocs" or the "Company") (NASDAQ: DOX) from December 13, 2016, through March 30, 2021 (the "Class Period") The lawsuit filed in the United States District Court for the Central District of California alleges violations of the Securities Exchange Act of 1934.
The Chicago Cubs hope to stay on schedule amid a coronavirus scare that’s landed four players on the COVID-19 injured list the past two days. Scheduled starter Kyle Hendricks was scratched Tuesday after the right-hander indicated he wasn’t feeling well — the team didn’t immediately provide more info on his status, other than to say the move was made out of caution. Bullpen coach Chris Young and first base coach Craig Driver have been flagged for positive tests.
Erik Denton was supposed to see his three young children last Sunday, the one day every other week that he was allowed to be with them. Three-year-old Joanna, her 2-year-old brother, Terry, and 6-month-old sister, Sierra, had been staying with their mother — Denton's ex-girlfriend — in Los Angeles. Fearful for their safety, their father had petitioned the court for custody March 1, alleging their mother, Liliana Carrillo, was delusional and had taken the kids and refused to tell him where they were.
Roman Josi (Nashville Predators) with a Goal vs. Tampa Bay Lightning, 04/13/2021
Tesla, Nvidia and Adobe are among actionable stocks while Bitcoin hit a record high ahead of the Coinbase IPO. JPMorgan earnings are on tap.
Country singer Morgan Wallen announced Tuesday he wouldn't be performing this summer.
The Singapore-based firm started as a ride-hailing company and has since expanded.
Dubber Corporation Limited (ASX: DUB) (Dubber), today announced that it has extended its Unified Call Recording footprint with the global availability of Dubber with Zoom Video Communications, Inc.'s (NASDAQ: ZM) video-first unified communications platform.
Cubs coaches Craig Driver and Chris Young recommend the COVID-19 vaccine, according to manager David Ross.
Incident marks second collision scare for Tesla chief’s satellite in two years
A downtown Jersey City restaurant has now found itself in hot water once again after a video emerged that appears to show them targeting Black patrons with their dress code requirements. According to NJ.com, last Saturday, Charles “CJ” Pace, 25, and his two friends went attempted to have lunch at The Ashford on Newark Avenue when he was told by an employee that he could not dine inside the venue because he was wearing “joggers” sweatpants. Pace and his companions – all of whom were Black – thought nothing of the dress code and dined outside without issue.
Colton Sissons (Nashville Predators) with a Goal vs. Tampa Bay Lightning, 04/13/2021
Members of the media are invited to an important announcement regarding public and road infrastructure with Gudie Hutchings, Parliamentary Secretary to the Minister for Women and Gender Equality and Rural Economic Development and Member of Parliament for Long Range Mountains, on behalf of the Honourable Maryam Monsef, Minister for Women and Gender Equality and Rural Economic Development; the Honourable Elvis Loveless, Minister of Transportation and Infrastructure, and the Honourable Andrew Parsons, Minister of Industry, Energy and Technology.
With a goal of 100% of students learning in-person this coming school year, the Miami-Dade County school district reconvened its task force of public health and medical experts to see what it could do to make “normal” a reality again.
EXCLUSIVE: The 1999 neo-noir thriller movie Arlington Road is eying a return as a TV series. Paramount+ is in early stages of development on the project, from the film’s director Mark Pellington. The Alienist co-executive producer Seth Fisher is writing the TV series adaptation. CBS Studios and Village Roadshow are co-producing. Pellington, who is set to […]
Brittany Cartwright and Jax Taylor, who wed in June 2019, announced they were expecting their first baby together in September
New therapeutic options for Non-cystic Fibrosis Bronchiectasis treatment as 5+ companies are working for the drug profiles.Los Angeles, USA, April 13, 2021 (GLOBE NEWSWIRE) -- Non-cystic Fibrosis Bronchiectasis Treatment 2021 | Prominent Players, Pipeline Growth, Future Trends, Unmet Demands, Emerging Therapies: DelveInsight New therapeutic options for Non-cystic Fibrosis Bronchiectasis treatment as 5+ companies are working for the drug profiles. DelveInsight’s “Non-cystic Fibrosis Bronchiectasis (NCFBE) Pipeline Insight” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Non-cystic Fibrosis Bronchiectasis pipeline landscapes. It comprises NCFBE pipeline drug profiles, including clinical and non-clinical stage products. It also includes the NCFBE therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Non-cystic Fibrosis Bronchiectasis pipeline products. Some of the key takeaways of the Non-cystic Fibrosis Bronchiectasis Pipeline Report Approximately 5+ key companies are developing Non-cystic Fibrosis Bronchiectasis therapies. These key players are TSRL Inc, Santhera Pharmaceuticals, Chiesi Farmaceutici, Novartis, InsMed, Zambon, and others have their NCFBE drug candidates in the different phases of clinical development. In September 2020, the U.S. biotech Insmed trumpeted updated phase 2 data from its brensocatib showing the drug prolonged time to exacerbations caused by the rare lung disease known as Non-cystic Fibrosis Bronchiectasis (NCFBE). Insmed develops INS1007, an investigational, first-in-class, oral, selective, reversible inhibitor of dipeptidyl peptidase I (DPP1) designed to treat Non-cystic Fibrosis Bronchiectasis patients. The U.S. Food and Drug Administration (FDA) has permitted breakthrough therapy designation for brensocatib (formerly known as INS1007) to treat adult patients with Non-cystic Fibrosis Bronchiectasis for reducing exacerbations. Brensocatib, a minor oral molecule, was initially developed by AstraZeneca before being licensed to Insmed in 2016. Zambon is conducting a double-blind, placebo-controlled, multi-centre clinical trial to investigate the efficacy and safety of therapy with inhaled colistimethate sodium in subjects with non-cystic fibrosis bronchiectasis chronically infected with pseudomonas aeruginosa (P. Aeruginosa). This trial is anticipated to be completed by May 2021. Insmed has initiated a Phase III clinical trial for INS1007 in Decemeber, 2021 which is anticipated to get completed in March, 2024. Get an overview of pipeline landscape @ Non-cystic Fibrosis Bronchiectasis Clinical Trial Analysis Non-cystic Fibrosis Bronchiectasis is a progressive respiratory disease characterised by permanent dilation of bronchi, mucus retention, and ciliary clearance impairment. The Bronchiectasis treatment focuses on managing symptoms, slowing decline in lung function and preventing exacerbations. Chest physiotherapy is an acknowledged treatment in terms of side effects. Some patients may react to more specialist treatments such as regular antibiotics, mainly in a low dose of macrolide three times a week. Frailty and co-morbidities perform a role in determining the appropriateness of these treatments. Non-cystic Fibrosis Bronchiectasis Emerging Drugs Colistimethate sodium by Zambon SpA Colistimethate sodium is a polymixin antibiotic and bactericidal against susceptible Gram-negative bacteria. The drug is sent for clinical trials by Xellia Pharmaceuticals, Zambon’s long-standing partner, with which it shares the objective of coming of this formulation to NCFBE patients globally. Colistimethate sodium is one of the antibiotics against Pseudomonas aeruginosa infections, and the I-Neb AAD system is an inhalation system developed to confer nebulised medications into the lung. Antibiotics by inhalation have high drug concentrations in the airways, minimising systemic exposure and potential side effects. INS1007 by Insmed Incorporated INS1007 is an investigational, first-in-class, oral, selective, reversible inhibitor of dipeptidyl peptidase I (DPP1) developed by Insmed to treat Non-cystic Fibrosis Bronchiectasis patients. DPP1 is an enzyme held to activate neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when formed in the bone marrow. Neutrophils are the most common type of white blood cell and execute a vital role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils garner in the airways and result in major active NSPs that cause lung destruction and inflammation. INS1007 may lessen the damaging effects of inflammatory diseases by prohibiting DPP1 and its activation of NSPs. CHF 6333 by Chiesi Farmaceutici CHF 6333 is a medicinal product for treating Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis and undergoing clinical testing. The authorities have not yet approved it for the treatment. CHF6333 is an inhaled anti-inflammatory which mechanism of action is based on the inhibition of Human Neutrophil Elastase. For further information, refer to the detailed report @ NCFBE Pipeline Therapeutics Scope of Non-cystic Fibrosis Bronchiectasis Pipeline Drug Insight Coverage: Global Major Players: 5+ Key PlayersProminent Players: TSRL Inc, Santhera Pharmaceuticals, Chiesi Farmaceutici, Novartis, InsMed, Zambon, and many others. Key Drugs Profiles: 5+ ProductsPhases: Non-cystic Fibrosis Bronchiectasis Therapies Late-stage (Phase III) NCFBE Therapies Mid-stage (Phase II)Non-cystic Fibrosis Bronchiectasis Therapies Early-stage (Phase I) NCFBE Pre-clinical stage and Discovery candidates Discontinued and Inactive candidates Mechanism of Action: Leucocyte elastase inhibitorsDipeptidyl peptidase I inhibitorsProtein 30S ribosomal subunit inhibitorsCell membrane modulators Molecule Types: Stem Cell Therapy Small molecule Gene therapy Route of Administration: OralSubcutaneous Inhalation Intravenous Product Types: MonotherapyCombinationMono/Combination Key Questions regarding Current Non-cystic Fibrosis Bronchiectasis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report What are the current options for Non-cystic Fibrosis Bronchiectasis treatment?How many companies are developing therapies for the treatment of Non-cystic Fibrosis Bronchiectasis? How many are NCFBE emerging therapies in the early-stage, mid-stage, and late development stages to treat Non-cystic Fibrosis Bronchiectasis?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the NCFBE market? Which are the dormant and discontinued products and the reasons for the same?What is the unmet need for current therapies for the treatment of Non-cystic Fibrosis Bronchiectasis? What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing NCFBE therapies? What are the critical designations that have been granted for the emerging therapies for Non-cystic Fibrosis Bronchiectasis? How many patents are granted and pending for the emerging therapies to treat NCFBE? Table of Contents 1Non-cystic Fibrosis Bronchiectasis Report Introduction2NCFBE Executive Summary3Non-cystic Fibrosis Bronchiectasis Overview4NCFB– DelveInsight’s Analytical Perspective In-depth Commercial Assessment 5NCFBE Pipeline Therapeutics 6Non-cystic Fibrosis Bronchiectasis Late Stage Products (Phase III)6.1Colistimethate sodium: Zambon6.2INS-1007: InsMed7Non-cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II)7.1Tobramycin dry-powder inhalation: Novartis 8Non-cystic Fibrosis Bronchiectasis Early Stage Products (Phase I)8.1Lonodelestat: Santhera Pharmaceuticals9Non-cystic Fibrosis Bronchiectasis Therapeutic Assessment10NCFBE Inactive Products 11Company-University Collaborations (Licensing/Partnering) NCFB Analysis12Non-cystic Fibrosis Bronchiectasis Key Companies13Non-cystic Fibrosis Bronchiectasis Key Products14Non-cystic Fibrosis Bronchiectasis Unmet Needs15Non-cystic Fibrosis Bronchiectasis Market Drivers and Barriers16 Non-cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion17Non-cystic Fibrosis Bronchiectasis Analyst Views18Appendix19About DelveInsight Get a customised pipeline report @ Non-cystic Fibrosis Bronchiectasis Drugs Pipeline Report Related Reports Non-Cystic Fibrosis Bronchiectasis Market DelveInsight's Non-Cystic Fibrosis Bronchiectasis (NCFB) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Non-Cystic Fibrosis Bronchiectasis (NCFB) in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan. Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast DelveInsight's Non-Cystic Fibrosis Bronchiectasis (NCFB) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of NCFB. Vascular Grafts Pipeline Insight and Competitive Landscape Vascular Grafts Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Vascular Grafts market. Night Vision Disturbances Market DelveInsight's Night Vision Disturbances Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. Brain Cancer Market DelveInsight’s ‘Brain Cancer Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of Brain Cancer, historical and forecasted epidemiology of brain cancer. Adult T-Cell Leukemia-Lymphoma Market DelveInsight' s Adult T-Cell Leukemia-Lymphoma Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur firstname.lastname@example.org +1(919)321-6187 www.delveinsight.com
Craig Smith (Boston Bruins) with a Goal vs. Buffalo Sabres, 04/13/2021
Japanese conglomerate Toshiba Corp said its board would meet on Wednesday to discuss key executive appointments after widespread media reports that Chief Executive Nobuaki Kurumatani will step down. Kurumatani is planning to resign as he faces controversy over a $20 billion buyout bid from his former employer, CVC Capital Partners, a source with knowledge of his decision told Reuters on Tuesday. "Reports about the replacement of our president and CEO are not something we announced," Toshiba said in a statement.
(Bloomberg) -- Asian stocks fluctuated in early trade following gains in U.S. equities and bonds, as investors shrugged off a higher-than-forecast rise in U.S. inflation to focus on the path of the global recovery.Shares slipped in Japan and rose in South Korea and Australia. U.S. contracts were little changed following another all-time high for the S&P 500 and Nasdaq 100 indexes, as the White House said the vaccine campaign remains on track despite a pause in Johnson & Johnson doses amid concerns about blood clotting.Treasuries extended gains on a successful sale of 30-year bonds, which resolved concerns that poor demand could spark another bout of volatility. The U.S. dollar was steady in early Asia trade.In Asia, a sharp selloff in one of China’s largest bad-debt managers has shaken credit markets, raising concerns that other heavily leveraged borrowers may also stumble.The latest data showing U.S. consumer prices rose more than expected last month had little impact given the distortions surrounding the year-earlier slump in price pressures. The market response signals confidence that the recovery remains on track with support from central banks and government spending.“A lot of growth and inflation have already been priced into the market,” said Emily Roland, co-chief investment strategist at John Hancock Investment Management. “It’s almost as if you need to exceed those expectations in order to see a more pronounced reaction from markets.”Runaway inflation, along with higher borrowing costs and taxes, have replaced the pandemic as the top concerns for global fund managers, according to the latest Bank of America Corp. survey.Meanwhile, Bitcoin jumped to an all-time high, and the Nasdaq set a reference price of $250 for the direct listing of Coinbase Global Inc., the cryptocurrency exchange that will start trading Wednesday. Oil traded above $60 a barrel.Some key events to watch this week:Banks and financial firms begin reporting first-quarter earnings, including JPMorgan Chase & Co., Citigroup Inc., Bank of America Corp., Morgan Stanley, Goldman Sachs Group Inc.Economic Club of Washington hosts Fed Chair Jerome Powell for a moderated Q&A on Wednesday.U.S. Federal Reserve releases Beige Book on Wednesday.U.S. data including initial jobless claims, industrial production and retail sales come Thursday.China economic growth, industrial production and retail sales figures are on Friday.These are some of the main moves in financial markets:StocksS&P 500 futures were flat as of 9:05 a.m. in Tokyo. The index closed 0.3% higher.Japan’s Topix Index was 0.4% lower.South Korea’s Kospi Index edged up 0.2%.Australia’s S&P/ASX 200 Index was 0.3% higher.Hang Seng futures rose 0.3% earlier.CurrenciesThe Bloomberg Dollar Spot Index was little changed.The yen was up 0.2% at 108.86 per dollar.The euro was at $1.1955.The offshore yuan traded around 6.5431 per dollar.BondsThe yield on 10-year Treasuries was steady at 1.62% after slipping in U.S. trade.Australia’s 10-year yield was six basis points lower at 1.75%.CommoditiesWest Texas Intermediate crude rose 0.5% to $60.51 a barrel.Gold was at $1,745.53 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.